Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.

The entities involved

• Vertex Pharmaceuticals →

  American pharmaceutical company

  • CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.Sun 12:46
  • NIH funded pivotal research for drug development involving Vertex Pharmaceuticals.Wed 23:04
• Royal Bank of Canada →

  financial institution in Canada

  • MarketBeat is providing average rating data as Royal Bank of Canada issues a price target report regarding ConocoPhillips.Tue 14:20
  • Royal Bank of Canada increased its stake in the NYLI MacKay Muni Short Duration ETF on August 1, 2026.Tue 13:38
• TD Cowen →

  American investment bank

  • TD Cowen upgraded Maze Therapeutics shares to a strong-buy rating, with coverage reported by MarketBeat.Tue 14:53
  • Cantor Fitzgerald raised price targets and reaffirmed ratings, while TD Cowen adjusted its ratings for Paylocity on August 7, 2026.Mon 23:14
• Morgan Stanley →

  U.S. investment bank

  • Citigroup upgraded Next plc to a buy rating, while Santander and Morgan Stanley also issued rating updates on the company.Tue 14:42
  • Morgan Stanley cut its rating for Rentokil Initial on October 20, 2026.Tue 14:26

Related events

• TD Cowen, Royal Bank of Canada, and Morgan Stanley all raised price targets and ratings for Ralliant.Jul 7
• Royal Bank of Canada lifted its target price for Aurinia Pharmaceuticals Inc. on October 9, 2026.Oct 10
• Royal Bank of Canada raised its target price for DCH.Oct 9
• Royal Bank of Canada, Bank of America, and Morgan Stanley raised price targets for argenex.Jul 7
• TD Cowen cut its price target for Federated Hermes, while Royal Bank of Canada raised its price target for the company.Thu 09:21